Kumar Arvind, Asaf Belal B, Lingaraju Vijay C, Yendamuri Sai, Pulle Mohan V, Sood Jayashree
Department of Thoracic Surgery, Sir Ganga Ram Hospital, New Delhi, India.
Department of Thoracic Surgery, Sir Ganga Ram Hospital, New Delhi, India.
Ann Thorac Surg. 2017 Nov;104(5):1688-1694. doi: 10.1016/j.athoracsur.2017.06.038. Epub 2017 Sep 28.
Open decortication of advanced tuberculous empyema remains standard of care. As with other aspects of thoracic surgery, minimally invasive approaches are making inroads into procedures traditionally performed open. In this retrospective analysis, we sought to examine feasibility, efficacy, and outcomes of thoracoscopic decortication of stage III tuberculous empyema in our experience.
The records of all patients in whom thoracoscopic decortication of stage III tuberculous empyema was performed between March 2012 and December 2015 were examined. Demographic and perioperative data were analyzed to assess the surgical outcomes of this study group. To assess long-term efficacy, patients were followed for a minimum of 6 months.
One hundred patients fit the study criteria, of these 67 were men. Ninety cases were successfully completed thoracoscopically. Mean operative time was 204 ± 34.2 minutes with mean blood loss of 384 ± 28 mL. Median chest drain duration and hospital stay was 7 days. There was no perioperative deaths. Morbidity rate was 33%, composed mostly of prolonged air leak (29%). Six-month follow-up revealed completely expanded lung in all patients except one with small apical asymptomatic air space. Intraoperative cultures were positive for mycobacteria in 25% patients. Six (6%) of these patients had multidrug-resistant tuberculosis and required a modification in their antituberculous therapy.
Thoracoscopic decortication of advanced tuberculous empyema is feasible, safe, and effective with good short- and long-term results in selected patients. In a substantial portion of patients, operative cultures required modifying drug treatment to treat underlying tuberculosis.
晚期结核性脓胸的开放纤维板剥脱术仍是标准治疗方法。与胸外科的其他方面一样,微创方法正在逐渐应用于传统上采用开放手术的操作中。在这项回顾性分析中,我们试图根据自身经验探讨III期结核性脓胸胸腔镜纤维板剥脱术的可行性、有效性和治疗结果。
检查了2012年3月至2015年12月期间所有接受III期结核性脓胸胸腔镜纤维板剥脱术患者的记录。分析人口统计学和围手术期数据以评估该研究组的手术结果。为评估长期疗效,对患者进行了至少6个月的随访。
100例患者符合研究标准,其中67例为男性。90例手术成功通过胸腔镜完成。平均手术时间为204±34.2分钟,平均失血量为384±28毫升。胸腔引流管留置时间和住院时间的中位数均为7天。无围手术期死亡病例。发病率为33%,主要为持续性漏气(29%)。6个月的随访显示,除1例有小的无症状肺尖气腔外,所有患者的肺均完全复张。25%的患者术中培养出分枝杆菌阳性。其中6例(6%)患者患有耐多药结核病,需要调整抗结核治疗方案。
对于部分患者,晚期结核性脓胸胸腔镜纤维板剥脱术可行、安全且有效,短期和长期效果良好。在相当一部分患者中,手术培养结果需要调整药物治疗以治疗潜在的结核病。